Difficulty: Medium
Average Score: 72%
Practice
The following inhibit platelet activation and/or aggregation:
Correct answer
D
Rationale
The correct answer is D) Prostacyclin (epoprostenol) because prostacyclin is a potent inhibitor of platelet activation and aggregation. Prostacyclin functions by increasing intracellular levels of cyclic adenosine monophosphate (cAMP) in platelets, leading to inhibition of platelet aggregation. This mechanism makes it an important drug in the treatment of conditions like pulmonary arterial hypertension and thromboembolic disorders.
A) Warfarin is a vitamin K antagonist that inhibits the synthesis of clotting factors in the liver, but it does not directly inhibit platelet activation or aggregation.
B) Heparin is an anticoagulant that works by enhancing the activity of antithrombin III, leading to inhibition of thrombin and factor Xa. While it prevents the formation of new clots, it does not directly inhibit platelet activation or aggregation.
C) Thromboxane A2 is a potent platelet activator and inducer of aggregation. It promotes vasoconstriction and platelet aggregation, working in contrast to the desired effect of inhibiting platelet activation and aggregation.
In an educational context, understanding the mechanisms of action of different cardiovascular drugs is crucial for healthcare professionals to make informed decisions in patient care. Knowing which drugs inhibit platelet activation and aggregation can help in managing conditions like thrombosis and cardiovascular diseases effectively. Prostacyclin's role in inhibiting platelet function is essential knowledge for pharmacology students and healthcare providers working in cardiology and related fields.
A) Warfarin is a vitamin K antagonist that inhibits the synthesis of clotting factors in the liver, but it does not directly inhibit platelet activation or aggregation.
B) Heparin is an anticoagulant that works by enhancing the activity of antithrombin III, leading to inhibition of thrombin and factor Xa. While it prevents the formation of new clots, it does not directly inhibit platelet activation or aggregation.
C) Thromboxane A2 is a potent platelet activator and inducer of aggregation. It promotes vasoconstriction and platelet aggregation, working in contrast to the desired effect of inhibiting platelet activation and aggregation.
In an educational context, understanding the mechanisms of action of different cardiovascular drugs is crucial for healthcare professionals to make informed decisions in patient care. Knowing which drugs inhibit platelet activation and aggregation can help in managing conditions like thrombosis and cardiovascular diseases effectively. Prostacyclin's role in inhibiting platelet function is essential knowledge for pharmacology students and healthcare providers working in cardiology and related fields.